Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Cerilliant
Teva
Chinese Patent Office
Fish and Richardson
Mallinckrodt
Merck
US Department of Justice
Covington

Generated: June 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 208552

« Back to Dashboard

NDA 208552 describes RHOFADE, which is a drug marketed by Allergan Inc and is included in one NDA. It is available from one supplier. There are four patents protecting this drug. Additional details are available on the RHOFADE profile page.

The generic ingredient in RHOFADE is oxymetazoline hydrochloride. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the oxymetazoline hydrochloride profile page.
Summary for 208552
Tradename:RHOFADE
Applicant:Allergan Inc
Ingredient:oxymetazoline hydrochloride
Patents:4
Formulation / Manufacturing:see details
Pharmacology for NDA: 208552
Medical Subject Heading (MeSH) Categories for 208552
Suppliers and Packaging for NDA: 208552
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
RHOFADE oxymetazoline hydrochloride CREAM;TOPICAL 208552 NDA Allergan 0023-5300 N 0023-5300-30
RHOFADE oxymetazoline hydrochloride CREAM;TOPICAL 208552 NDA Allergan 0023-5300 N 0023-5300-35

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CREAM;TOPICALStrength1%
Approval Date:Jan 18, 2017TE:RLD:Yes
Regulatory Exclusivity Expiration:Jan 18, 2020
Regulatory Exclusivity Use:NEW PRODUCT
Patent:➤ Sign UpPatent Expiration:May 2, 2028Product Flag?Substance Flag?Delist Request?
Patented Use:TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS WITH 1% OXYMETAZOLINE HYDROCHLORIDE CREAM
Patent:➤ Sign UpPatent Expiration:Aug 2, 2024Product Flag?Substance Flag?Delist Request?
Patented Use:TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS WITH 1% OXYMETAZOLINE HYDROCHLORIDE CREAM

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Cipla
Baxter
Boehringer Ingelheim
Fish and Richardson
Fuji
Medtronic
Moodys
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.